TriSalus Life Sciences, Inc. (TLSI) Discusses Revolutionary Approaches for Thyroid Artery Embolization and Tumor-Focused Therapies December 15, 2025 2:00 PM EST
Firm Contributors
Mary Szela – CEO, President & Director
Richard Marshall – Medical Director
Richard Marshak – Chief Industrial Officer
Andrea Marasso – Vice President of Advertising and marketing
Convention Name Contributors
Juan Camacho
Nelson Cox – Lake Avenue Capital Markets, LLC, Analysis Division
William Plovanic – Canaccord Genuity Corp., Analysis Division
Carl Byrnes – Northland Capital Markets, Analysis Division
Presentation
Operator
Good afternoon, and welcome to the TriSalus Life Sciences Digital KOL occasion. [Operator Instructions] As a reminder, this name is being recorded, and a replay can be made out there on the TriSalus web site following the conclusion of the occasion. I would now like to show the decision over to Mary Szela, Chief Govt Officer and President at TriSalus Life Sciences. Please go forward, Mary.
Mary Szela
CEO, President & Director
Thanks, and thanks all for becoming a member of at the moment. I am actually excited to kick off this session with Dr. Juan Camacho, who has innovated a really revolutionary new strategy for Thyroid Artery Embolization. And earlier than we dive into that info, let me do a fast overview of TriSalus. So in case you can advance the slide to only a transient overview slide, I believe it is in 2. And TriSalus is an organization that’s targeted on bettering outcomes for sufferers with strong tumors within the liver, the pancreas, and you may go to the subsequent slide, Dr. Camacho, maintain going to the subsequent one, this one, TriSalus At a Look. And so our mission is to enhance outcomes in sufferers who’ve tumors within the liver, within the pancreas and different strong tumors. And we try this via a platform know-how that may truly modulate strain and circulation to ship extra remedy into the tumor and stop any off-target supply.
